鲁抗医药
(600789)
| 流通市值：90.05亿 | | | 总市值：90.05亿 |
| 流通股本：8.99亿 | | | 总股本：8.99亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 786,358,617.39 | 716,996,053 | 703,936,711.12 | 772,536,945.22 |
| 交易性金融资产 | 0 | 0 | - | 1,220,160 |
| 应收票据及应收账款 | 955,387,979.32 | 1,103,764,942.54 | 1,223,580,194.14 | 940,440,122.12 |
| 应收账款 | 955,387,979.32 | 1,103,764,942.54 | 1,223,580,194.14 | 940,440,122.12 |
| 应收款项融资 | 442,313,517.64 | 444,234,258.86 | 405,745,917.21 | 496,587,244.23 |
| 预付款项 | 63,181,322.18 | 37,416,314.2 | 78,107,145.27 | 49,730,071.3 |
| 其他应收款合计 | 265,429,271.26 | 325,893,734.32 | 375,206,468 | 354,780,622.27 |
| 存货 | 1,266,992,024.09 | 1,258,666,581.05 | 1,359,188,675.35 | 1,484,208,209.11 |
| 其他流动资产 | 34,784,197.7 | 29,662,263.42 | 23,571,726.28 | 30,798,429.37 |
| 流动资产合计 | 3,814,446,929.58 | 3,916,634,147.39 | 4,169,336,837.37 | 4,130,301,803.62 |
| 非流动资产: | | | | |
| 长期股权投资 | 66,985,599.84 | 68,021,555.28 | 68,888,897.26 | 70,196,407.68 |
| 其他权益工具投资 | 15,818,043.94 | 16,417,126.21 | 16,498,146.82 | 17,804,315.99 |
| 投资性房地产 | 45,291,528.9 | 45,876,364.42 | 40,874,618 | 41,542,566.32 |
| 固定资产 | 3,521,977,199.92 | 3,578,008,406.03 | 3,655,241,733.02 | 3,710,666,844.9 |
| 在建工程 | 285,773,023.24 | 242,311,975.29 | 169,169,811.07 | 121,858,867.39 |
| 无形资产 | 778,340,228.64 | 784,077,942.74 | 760,544,098.51 | 766,203,266.06 |
| 开发支出 | 167,167,181.92 | 149,719,682.34 | 145,874,093.87 | 127,280,307.33 |
| 长期待摊费用 | 953,666.74 | 1,051,811.41 | 1,246,598.7 | 1,121,634.11 |
| 递延所得税资产 | 22,718,937.5 | 22,712,590.24 | 23,597,869.12 | 24,026,545.78 |
| 其他非流动资产 | 96,894,822.21 | 62,531,387.87 | 84,634,275.97 | 86,982,317.24 |
| 非流动资产合计 | 5,001,920,232.85 | 4,970,728,841.83 | 4,966,570,142.34 | 4,967,683,072.8 |
| 资产总计 | 8,816,367,162.43 | 8,887,362,989.22 | 9,135,906,979.71 | 9,097,984,876.42 |
| 流动负债: | | | | |
| 短期借款 | 1,038,320,911.92 | 915,130,842.18 | 964,145,432.39 | 871,771,193.79 |
| 应付票据及应付账款 | 1,105,138,118.26 | 1,268,976,331.86 | 1,442,414,231.06 | 1,502,685,721.71 |
| 其中：应付票据 | 255,858,000 | 480,872,944.89 | 613,316,819.17 | 602,428,121.69 |
| 应付账款 | 849,280,118.26 | 788,103,386.97 | 829,097,411.89 | 900,257,600.02 |
| 合同负债 | 71,765,164.08 | 61,075,946.2 | 88,081,728.16 | 104,655,572.38 |
| 应付职工薪酬 | 16,745,419.93 | 17,692,754.97 | 14,254,372.67 | 16,442,255.84 |
| 应交税费 | 24,040,215.96 | 28,010,632.38 | 31,726,391.56 | 21,829,493.16 |
| 其他应付款合计 | 204,721,333.01 | 222,696,298.46 | 263,095,344.83 | 250,539,831.37 |
| 应付股利 | 2,683,705.49 | 1,680,905.49 | 1,680,905.49 | 1,680,905.49 |
| 一年内到期的非流动负债 | 723,382,257.89 | 626,018,435.69 | 446,363,890.63 | 282,557,078.4 |
| 其他流动负债 | 6,556,019.82 | 6,110,523.61 | 9,498,234.47 | 10,450,921.97 |
| 流动负债合计 | 3,190,669,440.87 | 3,145,711,765.35 | 3,259,579,625.77 | 3,060,932,068.62 |
| 非流动负债: | | | | |
| 长期借款 | 1,241,790,000 | 1,363,960,000 | 1,447,860,000 | 1,685,900,000 |
| 长期应付款 | 123,857,705 | 123,857,705 | 123,857,705 | 123,857,705 |
| 递延收益 | 155,220,624.46 | 162,484,304.36 | 161,896,194.56 | 165,724,728.06 |
| 非流动负债合计 | 1,520,868,329.46 | 1,650,302,009.36 | 1,733,613,899.56 | 1,975,482,433.06 |
| 负债合计 | 4,711,537,770.33 | 4,796,013,774.71 | 4,993,193,525.33 | 5,036,414,501.68 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 898,669,632 | 898,669,632 | 898,669,632 | 898,669,632 |
| 资本公积 | 1,698,137,293.88 | 1,698,137,293.88 | 1,698,137,293.88 | 1,698,137,293.88 |
| 其他综合收益 | -24,181,956.06 | -23,582,873.79 | -23,501,853.18 | -22,195,684.01 |
| 专项储备 | 1,419,858.77 | 1,488,399.77 | 1,240,288.77 | 1,140,010.53 |
| 盈余公积 | 207,388,115.67 | 207,388,115.67 | 207,388,115.67 | 207,388,115.67 |
| 未分配利润 | 1,175,591,052.2 | 1,162,050,245.62 | 1,213,643,496.17 | 1,135,045,846.28 |
| 归属于母公司股东权益合计 | 3,957,023,996.46 | 3,944,150,813.15 | 3,995,576,973.31 | 3,918,185,214.35 |
| 少数股东权益 | 147,805,395.64 | 147,198,401.36 | 147,136,481.07 | 143,385,160.39 |
| 股东权益合计 | 4,104,829,392.1 | 4,091,349,214.51 | 4,142,713,454.38 | 4,061,570,374.74 |
| 负债和股东权益合计 | 8,816,367,162.43 | 8,887,362,989.22 | 9,135,906,979.71 | 9,097,984,876.42 |
| 公告日期 | 2025-10-31 | 2025-08-28 | 2025-04-30 | 2025-03-22 |
| 审计意见(境内) | | | | 标准无保留意见 |